Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FER | P16591 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23752448 | 1.00 | TGM2 (0.61) | TGM2CES1MAOAMAOBLRRK2 | |
| SCHEMBL12589678 | 0.94 | TGM2 (0.57) | TGM2CES1MAOAMAOBLRRK2 | |
| SCHEMBL15165815 | 0.91 | TGM2 (0.69) | TGM2CES1LRRK2CCNB2CDK1 | |
| SCHEMBL21479904 | 0.90 | MAOA (0.49) | TGM2CES1MAOAMAOBLRRK2 | |
| SCHEMBL22300036 | 0.90 | MAOA (0.49) | TGM2CES1MAOAMAOBLRRK2 | |
| Indirubin SCHEMBL20535353 | 0.84 | MAOA (0.64) | TGM2MAOAMAOBLRRK2KDM4E | |
| Indirubin SCHEMBL6809175 | 0.84 | MAOA (0.64) | TGM2MAOAMAOBLRRK2KDM4E | |
| Indirubin SCHEMBL27678 | 0.84 | MAOA (0.64) | TGM2MAOAMAOBLRRK2KDM4E | |
| Indirubin SCHEMBL9899338 | 0.84 | MAOA (0.64) | TGM2MAOAMAOBLRRK2KDM4E | |
| Indirubin SCHEMBL31032717 | 0.84 | MAOA (0.64) | TGM2MAOAMAOBLRRK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | claimed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | claimed |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2015-03-26 | — | — | US | claimed |
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3600259-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | Phosphorex, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2018183631-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | PHOSPHOREX, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2015-03-26 | — | — | US | disclosed |
| US-7572923-B2 | CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime | ANYGEN CO., LTD. (KR) | 2009-08-11 | — | — | US | disclosed |
| US-20070155816-A1 | CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime | ANYGEN CO., LTD. (KR) | 2007-07-05 | — | — | US | disclosed |
| EP-1713474-A1 | INDIRUBIN DERIVATIVES HAVING ANTICANCER PROPERTY AGAINST HUMAN CANCER CELL ME | Anygen Co., Ltd. (KR) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070416-A1 | INDIRUBIN DERIVATIVES HAVING ANTICANCER PROPERTY AGAINST HUMAN CANCER CELL ME | ANYGEN CO., LTD. (KR) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | TGM2 815/4885CES1 647/4885MAOA 543/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | TGM2 2971/4885CES1 888/4885MAOA 698/4885 |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | TGM2 815/4885CES1 647/4885MAOA 543/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | TGM2 2971/4885CES1 888/4885MAOA 698/4885 |
| US-20070155816-A1 | CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime | CDK7, CDKL5, CDK3 | TGM2 2543/4885CES1 3221/4885MAOA 2666/4885 |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | CYP7A1, CYP3A7, UGT2B7 | TGM2 1072/4885CES1 475/4885MAOA 217/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | TGM2 2971/4885CES1 888/4885MAOA 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.